These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 4156503)

  • 21. Effect of the specific angiotensin antagonist (Sar1) (Ala8) angiotensin II on blood pressure and the renin-angiotensin system in the conscious pregnant ewe and fetus.
    Broughton Pipkin F; O'Brien PM
    Am J Obstet Gynecol; 1978 Sep; 132(1):7-15. PubMed ID: 696788
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiologic determinants and clinical applications of angiotensin II blockade in hypertensive disorders.
    Parra-Carrillo JZ; Baer L; Radichevich I
    Cardiovasc Clin; 1978; 9(1):183-95. PubMed ID: 667880
    [No Abstract]   [Full Text] [Related]  

  • 23. Effect of saralasin on plasma aldosterone in hypertensive man.
    Brown RD; Tucker R; Tue K; Wisgerhof M; Salassa R
    J Lab Clin Med; 1978 Mar; 91(3):473-9. PubMed ID: 627750
    [No Abstract]   [Full Text] [Related]  

  • 24. Blockade of the systemic and renal vascular actions of angiotensisn II with the 1-sar, 8-ala analogue in the rat.
    Ishikawa I; Hollenberg NK
    Life Sci; 1975 Jul; 17(1):121-9. PubMed ID: 1143005
    [No Abstract]   [Full Text] [Related]  

  • 25. Saralasin in human hypertension: the early experience.
    Brunner HR; Laragh JH
    Kidney Int Suppl; 1979 Mar; (9):S36-43. PubMed ID: 289862
    [No Abstract]   [Full Text] [Related]  

  • 26. [Effect of saralasin on blood pressure, plasma renin and plasma noradrenaline in hypertensive patients].
    Bönner G; Lang R; Hummerich W; Helber A; Meurer KA; Wambach G; Kaufmann W
    Med Welt; 1980 Sep; 31(38):1362, 1363-5. PubMed ID: 7001167
    [No Abstract]   [Full Text] [Related]  

  • 27. Angiotensin II blockade in patients with essential hypertension.
    Aust N Z J Med; 1976 Aug; 6(3 Suppl):61-3. PubMed ID: 1071407
    [No Abstract]   [Full Text] [Related]  

  • 28. Hormonal responses to angiotensin blockade. Comparison between receptor antagonism and converting enzyme inhibition.
    Johnston CI; Millar JA; Casley DJ; McGrath BP; Matthews PG
    Circ Res; 1980 Jun; 46(6 Pt 2):I128-34. PubMed ID: 6247084
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of angiotensin II blockade by saralasin in normal man.
    Noth RH; Tan SY; Mulrow PJ
    J Clin Endocrinol Metab; 1977 Jul; 45(1):10-5. PubMed ID: 874056
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Detection of renovascular hypertension: saralasin test versus renin determinations.
    Marks LS; Maxwell MH; Smith RB; Cahill PJ; Kaufman JJ
    J Urol; 1976 Oct; 116(4):406-9. PubMed ID: 1053323
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparison of the biological effects of two angiotensin II analogues in hypertensive patients with sodium depletion.
    Hata T; Ogihara T; Mikami H; Nakamaru M; Maruyama A; Mandai T; Kumahara Y
    Life Sci; 1978 Jun; 22(21):1955-62. PubMed ID: 672437
    [No Abstract]   [Full Text] [Related]  

  • 32. In vivo effects of angiotensin antagonists on plasma aldosterone in the dog.
    Beckerhoff R; Uhlschmid G; Furrer J; Nussberger J; Schmied UR; Vetter WJ; Siegenthaler W
    Eur J Pharmacol; 1975 Dec; 34(2):363-7. PubMed ID: 1234555
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Response to saralasin and angiotensin's role in essential and renal hypertension.
    Hollenberg NK; Williams GH; Adams DF; Moore T; Brown C; Borucki LJ; Leung F; Bavli S; Solomon HS; Passan D; Dluhy R
    Medicine (Baltimore); 1979 Mar; 58(2):115-27. PubMed ID: 431398
    [No Abstract]   [Full Text] [Related]  

  • 34. Effect of the angiotensin II antagonist saralasin on plasma aldosterone concentration and on blood pressure before and during sodium depletion in normal subjects.
    Agabiti-Rosei E; Brown JJ; Brown WC; Fraser R; Trust PM; Lever AF; Morton JJ; Robertson JI
    Clin Endocrinol (Oxf); 1979 Mar; 10(3):227-34. PubMed ID: 455738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Angiotensin II blockade and the functions of the renin-angiotensin system.
    Davis JO; Freeman RH; Watkins BE; Stephens GA; Williams GM
    Prog Biochem Pharmacol; 1976; 12():1-15. PubMed ID: 798202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The effects of the angiotensin II antagonist saralasin on blood pressure and plasma aldosterone in man in relation to the prevailing plasma angiotensin II concentration.
    Brown JJ; Brown WC; Fraser R; Lever AF; Morton JJ; Robertson JI; Rosei EA; Trust PM
    Prog Biochem Pharmacol; 1976; 12():230-41. PubMed ID: 1019166
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Angiotensin blockade in renovascular hypertension: a controlled, prospective study.
    Marks LS; Maxwell MH; Gross C; Waks U; Kaufman JJ
    Br J Urol; 1977 Jun; 49(3):181-8. PubMed ID: 334316
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Humoral and neurogenic factors in two-kidney renovascular hypertension.
    de la Riva IJ; Basso N; Kurnjek ML; Taquini AC
    Arch Int Physiol Biochim; 1980 May; 88(2):137-46. PubMed ID: 6159837
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lowering of hypertension by central saralasin in the absence of plasma renin.
    Phillips MI; Mann JF; Haebara H; Hoffman WE; Dietz R; Schelling P; Ganten D
    Nature; 1977 Dec; 270(5636):445-7. PubMed ID: 593364
    [No Abstract]   [Full Text] [Related]  

  • 40. Haemodynamic profile of angiotensin II antagonism in essential hypertensive patients.
    Hunyor SN; Larkin H; Rowe J
    Clin Sci (Lond); 1979 Dec; 57 Suppl 5():119s-121s. PubMed ID: 396063
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.